Summary

Clostridium difficile, a Gram-positive, spore-forming, toxin-producing, non-invasive, anaerobic bacterium, is the causative organism of C. difficile infection (CDI), which is commonly associated with colitis, as well as C. difficile-associated diarrhea (CDAD) (ICD-10; A04.7) (ICD-10 Diagnosis Codes, 2016). The pathogen was first described in 1935 and can exist in spore and vegetative forms, with the spore form being resistant to heat, acid, and antibiotics (Hall and O’Toole, 1935).

The report considers Global CDI market to include sales of therapeutic and prophylactic agents aimed at treatment and prevention of CDIs across the 7MM. In 2016, it is estimated the total CDI market to be valued at $628.8m across the 7MM, and the US accounted for 91% of the market. Over the course of the 10-year forecast period, the CDI market will grow at a Compound Annual Growth Rate (CAGR) of 10.2% across the 7MM. The 5EU will experience the fastest growth with a CAGR of 19.2%, while the US and Japan will experience growth of 9.0% and 13.2%, respectively. At the end of 2026, the US will contribute around 81% of global sales, while the 5EU and Japan will account for around 17% and 2% of sales, respectively.

Major drivers in growth for the CDI market include -

  • The projected launch of prophylactic options for the prevention of C. difficile, led by Sanofi Pasteur’s toxoid vaccine ACAM-CDIFF.
  • The projected launch of microbiologic approaches for the treatment of recurrent CDI (rCDI), with the potential to leverage the efficacy of fecal microbiota transplants (FMT).
  • The projected launch of novel antibiotics for the treatment of CDI, positioned to reduce the rate of CDI recurrence.
  • A projected increase in the incidence of CDI in the US, driven by a higher incidence of community-associated CDI (CA-CDI).



During the 10-year forecast period, there are nine products that are on track to a launch, contributing to a forecast growth in the 7MM at a CAGR of 10.2% from 2016 to 2026.

The report "OpportunityAnalyzer: Clostridium difficile Infections - Opportunity Analysis and Forecasts to 2026" provides Overview of CDI, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

In particular, this report provides the following -

  • Topline CDI market revenue from 2016-2026. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting CDI therapeutics and prophylactics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global CDI therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.



Companies mentioned in this report: GlaxoSmithKline, Shire, OpenBiome, Akthelia Pharmaceuticals, MGB Biopharma, Merck & Co.,, Actelion, Summit Therapeutics, Otsuka Pharmaceuticals, Seres Therapeutics, Rebiotix, Sanofi Pasteur, Pfizer, Valneva, Synthetic Biologics.


Scope

  • Overview of CDI, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline CDI market revenue from 2016-2026. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting CDI therapeutics and prophylactics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global CDI therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.




Reasons To Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global CDI therapeutics and prophylactics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CDI therapeutics and prophylactics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.